MYL3 Antibody

Code CSB-PA249474
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using CSB-PA249474(MYL3 Antibody) at dilution 1/45, on the right is treated with fusion protein. (Original magnification: ×200)
  • The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA249474(MYL3 Antibody) at dilution 1/45, on the right is treated with fusion protein. (Original magnification: ×200)
  • Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: CSB-PA249474(MYL3 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
MYL3
Alternative Names
Cardiac myosin light chain 1 antibody; CMH8 antibody; CMLC1 antibody; ELC of myosin antibody; Essential light chain of myosin antibody; MLC1SB antibody; MLC1V antibody; MYL3 antibody; MYL3_HUMAN antibody; Myosin light chain 1 antibody; Myosin light chain 1 slow twitch muscle B/ventricular isoform antibody; Myosin light chain 1 slow, B antibody; Myosin light chain 3 antibody; Myosin, light chain 1, ventricular antibody; myosin, light chain 3, alkali, ventricular, skeletal, slow antibody; myosin, light polypeptide 3, alkali antibody; myosin, light polypeptide 3, alkali, ventricular, skeletal, slow antibody; OTTHUMP00000165922 antibody; Slow skeletal ventricular myosin alkali light chain 3 antibody; slow-twitch muscle B/ventricular isoform antibody; Ventricular/slow twitch myosin alkali light chain antibody; VLC1 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Fusion protein of Human MYL3
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,WB,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:2000-1:10000
WB 1:1000-1:5000
IHC 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Regulatory light chain of myosin. Does not bind calcium.
Gene References into Functions
  1. In Familial Hypertrophic Cardiomyopathy, the MYL3 Arg94His variant was associated with high disease penetrance and substantial interventricular septal hypertrophy PMID: 26443374
  2. N-fragment is the binding domain of human ventricular LC1, whereas the C-fragment serves as a functional domain, which may be more involved in the modulation of the actin-activated ATPase activity of myosin PMID: 14516912
  3. Cell-permeable peptide containing the 15 amino acid N-terminal peptide from human ventricular light chain-1 (VLC-1) enhanced myocardial contractility. PMID: 17717642
Involvement in disease
Cardiomyopathy, familial hypertrophic 8 (CMH8)
Database Links

HGNC: 7584

OMIM: 160790

KEGG: hsa:4634

STRING: 9606.ENSP00000292327

UniGene: Hs.517939

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*